MDGN 205Alternative Names: Glucagon-like peptide-2 gene therapy - Medgenics; MDGN-205; TARGTGLP-2™
Latest Information Update: 30 Dec 2016
At a glance
- Originator Medgenics
- Developer Aevi Genomic Medicine
- Class Gene therapies; Peptides
- Mechanism of Action Glucagon-like peptide 2 stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Short bowel syndrome